comparison the teraputic effect of pioglitazone and carnitine to metformin and carnitine in patients with non alcoholic fatty liver disease

Phase 3

Recruiting

• Conditions: non alcoholic fatty liver disease (NAFLD).; Fatty (change of) liver, not elsewhere classified; K76.0

• Registration Number: IRCT20190701044062N3
• Lead Sponsor: Tabriz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 6 October 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

17-50 years old
Paitents with non alcoholic fatty liver disease who have been ruled out all known causes of fatty liver disease including alcohol, medications, viral hepatitis, autoimmune hepatitis and metabolic causes such as Wilson and hemochromatosis and etc.

Exclusion Criteria

Patients with liver disease such as viral hepatitis, autoimmune hepatitis, Wilson, hemochromatosis, liver cirrhosis, and PBC and PSC
Patients who drink alcohol.
Patients with renal Failure ( Creatinine > 1.5 mg/dl)
Patients with known severe systemic disease and malignancy.
Pregnancy or breastfeeding
Patients with type 1 diabetes

Study & Design

• Study Type: interventional
• Study Design: Not specified